Candriam Luxembourg S.C.A. grew its holdings in Accuray Incorporated (NASDAQ:ARAY) by 163.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 218,191 shares of the medical equipment provider’s stock after purchasing an additional 135,338 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Accuray were worth $1,041,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mackay Shields LLC acquired a new stake in shares of Accuray in the 4th quarter valued at approximately $715,000. Two Sigma Advisers LP raised its position in shares of Accuray by 10.6% in the 4th quarter. Two Sigma Advisers LP now owns 139,719 shares of the medical equipment provider’s stock valued at $476,000 after acquiring an additional 13,389 shares during the period. Legal & General Group Plc raised its position in shares of Accuray by 9.6% in the 3rd quarter. Legal & General Group Plc now owns 1,366,100 shares of the medical equipment provider’s stock valued at $6,147,000 after acquiring an additional 119,149 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Accuray by 6.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,243,000 shares of the medical equipment provider’s stock valued at $10,094,000 after acquiring an additional 131,283 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Accuray by 58.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,015,496 shares of the medical equipment provider’s stock valued at $6,873,000 after acquiring an additional 741,493 shares during the period. 80.57% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ARAY opened at $3.94 on Thursday. The company has a market capitalization of $351.20 million, a P/E ratio of -14.07 and a beta of 1.97. The company has a debt-to-equity ratio of 3.06, a quick ratio of 1.03 and a current ratio of 1.71. Accuray Incorporated has a fifty-two week low of $3.16 and a fifty-two week high of $5.40.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Tuesday, April 23rd. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $103.22 million for the quarter, compared to the consensus estimate of $104.02 million. Accuray had a negative net margin of 3.85% and a negative return on equity of 25.91%. On average, analysts forecast that Accuray Incorporated will post -0.16 EPS for the current fiscal year.

ARAY has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Thursday, February 14th. BidaskClub downgraded shares of Accuray from a “hold” rating to a “sell” rating in a research report on Wednesday, April 10th. Finally, BTIG Research reiterated a “hold” rating on shares of Accuray in a research report on Wednesday, April 24th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $5.13.

In other Accuray news, CEO Joshua Levine sold 6,604 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total transaction of $29,982.16. Following the sale, the chief executive officer now directly owns 1,033,593 shares in the company, valued at approximately $4,692,512.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.40% of the company’s stock.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2019/05/16/candriam-luxembourg-s-c-a-acquires-135338-shares-of-accuray-incorporated-aray.html.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

See Also: What are earnings reports?

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.